Human UDP-glucuronosyltransferase isoforms involved in haloperidol glucuronidation and quantitative estimation of their contribution

Drug Metabolism and Disposition

Volumn 40, Issue 2, 2012, Pages 240-248

  Kato, Yukiko ^a   Nakajima, Miki ^a   Oda, Shingo ^a   Fukami, Tatsuki ^a   Yokoi, Tsuyoshi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; GEMFIBROZIL; GLUCURONIDE; GLUCURONOSYLTRANSFERASE 1A4; GLUCURONOSYLTRANSFERASE 1A9; GLUCURONOSYLTRANSFERASE 2B7; HALOPERIDOL; PROPOFOL; RECOMBINANT ENZYME; TRIFLUOPERAZINE; ZIDOVUDINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CATALYSIS; CHEMICAL REACTION; CONTROLLED STUDY; DRUG GLUCURONIDATION; DRUG SCREENING; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; LIVER MICROSOME; MALE; MOLECULAR PROBE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; ENZYME INHIBITORS; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HALOPERIDOL; HUMANS; ISOENZYMES; KINETICS; MALE; MICROSOMES, LIVER; MOLECULAR STRUCTURE; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; SPECIES SPECIFICITY; SUBSTRATE SPECIFICITY; URIDINE DIPHOSPHATE GLUCURONIC ACID;

EID: 84863401482     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.042150     Document Type: Article

References (30)

1. Court MH, Krishnaswamy S, Hao Q, Duan SX, Patten CJ, Von Moltke LL, and Greenblatt DJ (2003) Evaluation of 3′-azido-3′-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism. Drug Metab Dispos 31:1125-1133. (Pubitemid 37048284)
2. Crespi CL (1995) Xenobiotic-metabolizing human cells as tools for pharmacological and toxicological research. Adv Drug Res 26:179-235.
3. Forsman A and Ohman R (1976) Pharmacokinetic studies on haloperidol in man. Curr Ther Res Clin Exp 20:319-336.
4. Fujiwara R, Nakajima M, Yamanaka H, Nakamura A, Katoh M, Ikushiro S, Sakaki T, and Yokoi T (2007) Effects of coexpression of UGT1A9 on enzymatic activities of human UGT1A isoforms. Drug Metab Dispos 35:747-757. (Pubitemid 46641545)
5. Goff DC, Midha KK, Brotman AW, Waites M, and Baldessarini RJ (1991) Elevation of plasma concentrations of haloperidol after the addition of fluoxetine. Am J Psychiatry 148:790-792.
6. Gorrod JW and Fang J (1993) On the metabolism of haloperidol. Xenobiotica 23:495-508. (Pubitemid 23172550)
7. Green MD and Tephly TR (1996) Glucuronidation of amines and hydroxylated xenobiotics and endobiotics catalyzed by expressed human UGT1.4 protein. Drug Metab Dispos 24:356-363. (Pubitemid 26089830)
8. +-Glucuronidation, a common pathway in human metabolism of drugs with a tertiary amine group. Drug Metab Dispos 26:830-837.
9. Hirokane G, Someya T, Takahashi S, Morita S, and Shimoda K (1999) Interindividual variation of plasma haloperidol concentrations and the impact of concomitant medications: the analysis of therapeutic drug monitoring data. Ther Drug Monit 21:82-86. (Pubitemid 29077458)
10. Inaba T and Kovacs J (1989) Haloperidol reductase in human and guinea pig livers. Drug Metab Dispos 17:330-333. (Pubitemid 19140689)
11. Jann MW, Ereshefsky L, Saklad SR, Seidel DR, Davis CM, Burch NR, and Bowden CL (1985) Effects of carbamazepine on plasma haloperidol levels. J Clin Psychopharmacol 5:106-109. (Pubitemid 15149502)
12. King CD, Rios GR, Green MD, and Tephly TR (2000) UDP- glucuronosyltransferases. Curr Drug Metab 1:143-161.
13. Kudo S and Ishizaki T (1999) Pharmacokinetics of haloperidol: an update. Clin Pharmacokinet 37:435-456.
14. Linnoila M, Viukari M, Vaisanen K, and Auvinen J (1980) Effect of anticonvulsants on plasma haloperidol and thioridazine levels. Am J Psychiatry 137:819-821. (Pubitemid 10085120)
15. +-glucuronidation of aliphatic tertiary amines in human: antidepressant versus antipsychotic drugs. Xenobiotica 25:291-301.
16. Mackenzie PI, Bock KW, Burchell B, Guillemette C, Ikushiro S, Iyanagi T, Miners JO, Owens IS, and Nebert DW (2005) Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genomics 15:677-685. (Pubitemid 41345319)
17. Mano Y, Usui T, and Kamimura H (2006) Identification of human UDP-glucuronosyltransferase responsible for the glucuronidation of niflumic acid in human liver. Pharm Res 23:1502-1508. (Pubitemid 43993813)
18. Mano Y, Usui T, and Kamimura H (2007) The UDP-glucuronosyltransferase 2B7 isozyme is responsible for gemfibrozil glucuronidation in the human liver. Drug Metab Dispos 35:2040-2044. (Pubitemid 350005193)
19. Miners JO, Bowalgaha K, Elliot DJ, Baranczewski P, and Knights KM (2011) Characterization of niflumic acid as a selective inhibitor of human liver microsomal UDP-glucuronosyltransferase 1A9: application to the reaction phenotyping of acetaminophen glucuronidation. Drug Metab Dispos 39:644-652.
20. Nakajima M, Nakamura S, Tokudome S, Shimada N, Yamazaki H, and Yokoi T (1999) Azelastine N-demethylation by cytochrome P-450 (CYP)3A4, CYP2D6, and CYP1A2 in human liver microsomes: evaluation of approach to predict the contribution of multiple CYPs. Drug Metab Dispos 27:1381-1391.
21. Narayanan R, LeDuc B, and Williams DA (2004) Glucuronidation of haloperidol by rat liver microsomes: involvement of family 2 UDP-glucuronosyltransferases. Life Sci 74:2527-2539. (Pubitemid 38317117)
22. Oida T, Terauchi Y, Yoshida K, Kagemoto A, and Sekine Y (1989) Use of antisera in the isolation of human specific conjugate of haloperidol. Xenobiotica 19:781-793. (Pubitemid 19147795)
23. Pan L and Belpaire FM (1999) In vitro study on the involvement of CYP1A2, CYP2D6 and CYP3A4 in the metabolism of haloperidol and reduced haloperidol. Eur J Clin Pharmacol 55:599-604. (Pubitemid 29489207)
24. Pan LP, Wijnant P, De Vriendt C, Rosseel MT, and Belpaire FM (1997) Characterization of the cytochrome P450 isoenzymes involved in the in vitro N-dealkylation of haloperidol. Br J Clin Pharmacol 44:557-564. (Pubitemid 27517482)
25. Ramírez J, Mirkov S, Zhang W, Chen P, Das S, Liu W, Ratain MJ, and Innocenti F (2008) Hepatocyte nuclear factor-1 α is associated with UGT1A1, UGT1A9 and UGT2B7 mRNA expression in human liver. Pharmacogenomics J 8:152-161. (Pubitemid 351411552)
26. Shiratani H, Katoh M, Nakajima M, and Yokoi T (2008) Species differences in UDP-glucuronosyltransferase activities in mice and rats. Drug Metab Dispos 36:1745-1752.
27. Someya T, Shibasaki M, Noguchi T, Takahashi S, and Inaba T (1992) Haloperidol metabolism in psychiatric patients: importance of glucuronidation and carbonyl reduction. J Clin Psychopharmacol 12:169-174.
28. Staines AG, Sindelar P, Coughtrie MW, and Burchell B (2004) Farnesol is glucuronidated in human liver, kidney and intestine in vitro, and is a novel substrate for UGT2B7 and UGT1A1. Biochem J 384:637-645. (Pubitemid 40018978)
29. Uchaipichat V, Mackenzie PI, Elliot DJ, and Miners JO (2006) Selectivity of substrate (trifluoperazine) and inhibitor (amitriptyline, androsterone, canrenoic acid, hecogenin, phenylbutazone, quinidine, quinine, and sulfinpyrazone) "probes" for human UDP-glucuronosyltransferases. Drug Metab Dispos 34:449-456.
30. Yasui N, Kondo T, Otani K, Furukori H, Mihara K, Suzuki A, Kaneko S, and Inoue Y (1999) Effects of itraconazole on the steady-state plasma concentrations of haloperidol and its reduced metabolite in schizophrenic patients: in vivo evidence of the involvement of CYP3A4 for haloperidol metabolism. J Clin Psychopharmacol 19:149-154. (Pubitemid 29161960)